This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2003 Dec:92 Suppl 2:22-6.

doi: 10.1111/j.1465-5101.2003.04397.x.

The Finnish trial of prostate cancer screening: where are we now?

P Finne¹, U H Stenman, L Määttänen, T Mäkinen, T L J Tammela, P Martikainen, M Ruutu, M Ala-Opas, J Aro, P J Karhunen, J Lahtela, P Rissanen, H Juusela, M Hakama, A Auvinen

Affiliations

PMID: 14983949
DOI: 10.1111/j.1465-5101.2003.04397.x

Clinical Trial

The Finnish trial of prostate cancer screening: where are we now?

P Finne et al. BJU Int. 2003 Dec.

. 2003 Dec:92 Suppl 2:22-6.

doi: 10.1111/j.1465-5101.2003.04397.x.

Authors

P Finne¹, U H Stenman, L Määttänen, T Mäkinen, T L J Tammela, P Martikainen, M Ruutu, M Ala-Opas, J Aro, P J Karhunen, J Lahtela, P Rissanen, H Juusela, M Hakama, A Auvinen

Affiliation

¹ Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. patrik.finne@hus.fi

PMID: 14983949
DOI: 10.1111/j.1465-5101.2003.04397.x

No abstract available

PubMed Disclaimer

Similar articles

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N, Rissanen P, Tammela TLJ, Kujala P, Stenman UH, Taari K, Talala K, Auvinen A. Booth N, et al. PLoS One. 2019 Nov 5;14(11):e0224479. doi: 10.1371/journal.pone.0224479. eCollection 2019. PLoS One. 2019. PMID: 31689326 Free PMC article. Clinical Trial.
Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, Tammela TL, Auvinen A. Neupane S, et al. Int J Urol. 2018 Mar;25(3):270-276. doi: 10.1111/iju.13508. Epub 2017 Dec 10. Int J Urol. 2018. PMID: 29224236 Clinical Trial.
Biopsy diagnosis of prostatic cancer--current areas of concern.
Feneley MR, Parkinson MC. Feneley MR, et al. J Clin Pathol. 1997 Apr;50(4):265-6. doi: 10.1136/jcp.50.4.265. J Clin Pathol. 1997. PMID: 9215135 Free PMC article. No abstract available.
PSA Screening for Prostate Cancer.
Quaas J. Quaas J. Am Fam Physician. 2015 May 1;91(9):Online. Am Fam Physician. 2015. PMID: 25955746 Review. No abstract available.
The case for prostate cancer screening.
Andriole GL. Andriole GL. Semin Urol. 1993 May;11(2):50-3. Semin Urol. 1993. PMID: 7689738 Review.

See all similar articles

Cited by

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.
Pashayan N, Pharoah PD, Schleutker J, Talala K, Tammela TLj, Määttänen L, Harrington P, Tyrer J, Eeles R, Duffy SW, Auvinen A. Pashayan N, et al. Br J Cancer. 2015 Sep 29;113(7):1086-93. doi: 10.1038/bjc.2015.289. Epub 2015 Aug 20. Br J Cancer. 2015. PMID: 26291059 Free PMC article.
Prostate cancer risk prediction using a polygenic risk score.
Sipeky C, Talala KM, Tammela TLJ, Taari K, Auvinen A, Schleutker J. Sipeky C, et al. Sci Rep. 2020 Oct 13;10(1):17075. doi: 10.1038/s41598-020-74172-z. Sci Rep. 2020. PMID: 33051487 Free PMC article.
ANO7 is associated with aggressive prostate cancer.
Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium; Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J. Kaikkonen E, et al. Int J Cancer. 2018 Nov 15;143(10):2479-2487. doi: 10.1002/ijc.31746. Epub 2018 Sep 22. Int J Cancer. 2018. PMID: 30157291 Free PMC article.
Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non-protocol-based Follow-up and a Protocol-based Contemporary Follow-up.
Kalalahti I, Vasarainen H, Erickson AM, Siipola A, Tikkinen KAO, Rannikko A. Kalalahti I, et al. Eur Urol Open Sci. 2021 Oct 28;34:33-40. doi: 10.1016/j.euros.2021.09.016. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34934965 Free PMC article.
Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.
Walsh EI, Turner EL, Lane JA, Donovan JL, Neal DE, Hamdy FC, Martin RM; the CAP & ProtecT Trial Groups; Investigators; Research staff; Management Committee; CAP & ProtecT Trial Steering Committee; Data Monitoring Committee; Administrative staff. Walsh EI, et al. Trials. 2016 Oct 13;17(1):497. doi: 10.1186/s13063-016-1624-6. Trials. 2016. PMID: 27737692 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information